Home/Filings/4/0001548187-21-000080
4//SEC Filing

Remeditex Ventures LLC 4

Accession 0001548187-21-000080

CIK 0001548187other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 5:09 PM ET

Size

10.7 KB

Accession

0001548187-21-000080

Insider Transaction Report

Form 4
Period: 2021-12-16
Transactions
  • Disposition to Issuer

    Warrant (right to buy)

    2021-12-16250,0000 total
    Exercise: $16.00Exp: 2024-06-19Common Stock (250,000 underlying)
  • Disposition to Issuer

    Common Stock

    2021-12-16$22.60/sh9,214,277$208,242,6600 total
  • Disposition to Issuer

    Warrant (right to buy)

    2021-12-16170,8080 total
    Exercise: $12.88Exp: 2024-10-11Common Stock (170,808 underlying)
Footnotes (3)
  • [F1]Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest.
  • [F2]Remeditex Ventures LLC is the record and beneficial owner of the shares of common stock and the warrant to purchase common stock subject to this Form 4 and shares voting and dispositive power over such securities with Malachite Trust, the majority owner of Remeditex Ventures LLC and Lyda Hill. Ms. Hill is the Trustee of the Malachite Trust. By reason of such relationships, Ms. Hill, the Malachite Trust and Remeditex Ventures LLC may be deemed to share voting and dispositive power over the securities owned directly by Remeditex Ventures LLC. Remeditex Ventures LLC, the Malachite Trust and Lyda Hill each disclaims beneficial ownership of the reported securities except to the extent of its or her pecuniary interest therein.
  • [F3]Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.

Issuer

Soliton, Inc.

CIK 0001548187

Entity typeother
IncorporatedTX

Related Parties

1
  • filerCIK 0001627363

Filing Metadata

Form type
4
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 5:09 PM ET
Size
10.7 KB